Glycan recognition by DC-SIGN, Galectins, and Siglecs: structural insights and ligand-based drug design strategies- a review.
A framework for precision glycoimmunotherapy in cancer, infection, fibrosis, and autoimmunity is outlined, positioning lectins as dynamic immune checkpoints whose structural plasticity makes them compelling and tractable drug targets.